Cubist Pharmaceuticals entered into a research agreement with Evotec. Cubist will use Evotec’s fragment-screening technology, EVOlution™, to complement discovery efforts in two of its antibacterial programs. In addition, Evotec will access the synchrotron technology of Diamond Light Source, its partner for protein crystallography, to determine the 3-D structure of fragments bound to Cubist’s targets of interest.

EVOlution is Evotec’s approach to fragment-based drug discovery. It combines biochemical, nuclear magnetic resonance, and surface plasmon resonance screening technologies for the screening of low molecular weight compounds and fragments. 

Previous articleHealth Canada Clears DxS’ K-RAS Mutation Kit as Test for Anti-EGFR Therapies
Next articleLonza to Produce Anti-RhD Antibodies for LFB’s Phase III Trials